These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 32397021)
1. [The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia]. Fei XH; Gu JY; Yin YM; Cheng HY; Zhang WJ; Zhang SQ; Zhao J; Wang JB Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):578-583. PubMed ID: 32397021 [No Abstract] [Full Text] [Related]
2. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia]. Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329 [No Abstract] [Full Text] [Related]
3. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H Front Immunol; 2024; 15():1389227. PubMed ID: 38803489 [TBL] [Abstract][Full Text] [Related]
4. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis]. Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136 [No Abstract] [Full Text] [Related]
5. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990 [TBL] [Abstract][Full Text] [Related]
7. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062 [TBL] [Abstract][Full Text] [Related]
8. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. Ai H; Fu YW; Wang YQ; Wei XD; Song YP Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):827-830. PubMed ID: 31775481 [No Abstract] [Full Text] [Related]
9. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia. Xiao F; Guo H; Yan X; Qi M; Zhang J Transpl Immunol; 2024 Jun; 84():102037. PubMed ID: 38499049 [TBL] [Abstract][Full Text] [Related]
10. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant]. Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201 [No Abstract] [Full Text] [Related]
11. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia]. Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926 [TBL] [Abstract][Full Text] [Related]
12. [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. Yuan J; Ren H; Qiu Z; Li Y; Wang M; Liu W; Xu W; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):475-9. PubMed ID: 26134011 [TBL] [Abstract][Full Text] [Related]
13. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia]. Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271 [TBL] [Abstract][Full Text] [Related]
14. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
15. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512 [TBL] [Abstract][Full Text] [Related]
16. [Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]. Jin XS; Yang L; Wang BH; Li HH; Yu L; Jing Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1675-1682. PubMed ID: 28024476 [TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
18. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of patients with acute leukemia and central nervous system involvement undergoing allogeneic hematopoietic stem cell transplantation]. Liu J; Ma R; He Y; Luo XY; Han W; Han TT; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ Zhonghua Nei Ke Za Zhi; 2023 Nov; 62(11):1295-1302. PubMed ID: 37935495 [No Abstract] [Full Text] [Related]
20. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation]. Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063 [No Abstract] [Full Text] [Related] [Next] [New Search]